Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed May 19, 2016 · 10-Q · 49 days after period end · 0001564590-16-019683
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Net Income | -$4.55M | -$2.47M |
| EPS Diluted | -$7.10 | -$4.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Mar 31, 2016 · filed May 19, 2016 · 49 d after period end
